⬡NOVALYTELABS
COMPOUND REFERENCE

The research compound in Wegovy®

Wegovy® is a chronic weight management medicine from Novo Nordisk. Its active compound is Semaglutide — which is what this catalogue supplies, as a research material.

This is not Wegovy®, and NOVALYTE LABS has no affiliation with Novo Nordisk. We supply the compound Semaglutide for laboratory research only — not for human consumption, diagnostic, therapeutic or veterinary use. Wegovy® is a trademark of Novo Nordisk, referenced here only to identify the compound.

Wegovy is Novo Nordisk’s brand for semaglutide in weight management, at higher doses than the same compound carries under the Ozempic brand for diabetes.

The molecule is unchanged between the two: a long-acting GLP-1 receptor agonist designed to resist DPP-4 degradation and bind strongly to albumin.

Semaglutide is listed here as a research material with batch documentation, not as the branded medicine.

Semaglutide in this catalogue

NOVALYTESemaglutide0.25mg × 4 pensPrefilled injection penStore 2–8 °CRESEARCH USE ONLY
Metabolic ResearchSemaglutide

0.25mg × 4 pens

€449.90€292.90
View compound

How Semaglutide is supplied here

Everything below describes the research material in this catalogue, not the medicine. Semaglutide is stocked in 3 presentations, so the figures below are for the base one.

CompoundSemaglutide
Presentation0.25mg × 4 pens
Dosage options0.25mg × 4 pens · 1mg × 4 pens · 2.4mg × 4 pens
Research categoryMetabolic Research
Batch COACertificate supplied with order
AvailabilityIn stock
Intended useLaboratory research only — not for human or veterinary use

Common questions

What is the active compound in Wegovy?

Semaglutide. Wegovy is a registered trademark of Novo Nordisk, approved for chronic weight management.

Is this Wegovy?

No. NOVALYTE LABS supplies Semaglutide as a research material with batch documentation. It is not Wegovy, it is not a medicine, it is not supplied for human use, and there is no affiliation with Novo Nordisk.

Why is Semaglutide sold under more than one brand?

Because a brand is tied to an approved indication rather than to the molecule. Semaglutide is marketed as Wegovy and also as Ozempic — same compound, different approvals.

Other brands using Semaglutide

The same compound is marketed under more than one brand, usually because each brand carries a different approved indication.